Findings

What do systematic reviews say?

2 questions · 8 findings · 1 reviews · Gynaecological, Neuro-oncology and Orphan Cancer

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 12.5%Moderate 2 · 25%High 5 · 62.5%

Overall survival ( · people with HGG

Anti‐angiogenic therapy showed no clear difference in overall survival ( compared with no anti‐angiogenic therapy (high certainty).

4 findings from 1 review

Anti‐angiogenic therapy for high‐grade glioma 2018 · Cochrane Headline outcomes only
HR 0.95 [0.88, 1.02]
11 studies · 3743 participants
High
Anti‐angiogenic therapy for high‐grade glioma 2018 · Cochrane Headline outcomes only
HR 0.93 [0.86, 1.02]
8 studies · 2833 participants
High
Anti‐angiogenic therapy for high‐grade glioma 2018 · Cochrane Headline outcomes only
HR 0.99 [0.85, 1.16]
3 studies · 910 participants
Moderate

Show 1 more finding

Anti‐angiogenic therapy for high‐grade glioma 2018 · Cochrane Headline outcomes only
HR 0.92 [0.85, 1]
11 studies · 3506 participants
Low

Progression‐free survival · people with HGG

Anti‐angiogenic therapy leads to lower progression‐free survival ( compared with no anti‐angiogenic therapy (high certainty).

4 findings from 1 review

Anti‐angiogenic therapy for high‐grade glioma 2018 · Cochrane Headline outcomes only
HR 0.73 [0.68, 0.79]
10 studies · 3595 participants
High
Anti‐angiogenic therapy for high‐grade glioma 2018 · Cochrane Headline outcomes only
HR 0.75 [0.69, 0.82]
8 studies · 2833 participants
High
Anti‐angiogenic therapy for high‐grade glioma 2018 · Cochrane Headline outcomes only
HR 0.64 [0.54, 0.76]
2 studies · 762 participants
Moderate

Show 1 more finding

Anti‐angiogenic therapy for high‐grade glioma 2018 · Cochrane Headline outcomes only
HR 0.72 [0.66, 0.77]
10 studies · 3464 participants
High